黑龙江医药
黑龍江醫藥
흑룡강의약
HEILONGJIANG MEDICAL JOURNAL
2014年
3期
546-548,549
,共4页
C-erbB4/HER4%结肠癌%免疫组织化学
C-erbB4/HER4%結腸癌%免疫組織化學
C-erbB4/HER4%결장암%면역조직화학
C-erbB4/HER4%colon carcinoma%immunohistochemistry
目的:研究HER4在结肠癌中的表达并探讨其临床意义。方法:选择47例经哈尔滨医科大学附属肿瘤医院病理科确诊的结肠癌术后蜡块标本重新切片,经HE染色并由该院病理科医生重新阅片确诊;另取6例术后经病理检查证实为非恶性的结肠组织(视为良性结肠组织)作为对照,应用免疫组织化学方法(SP法)检测HER4在结肠癌各组癌组织及正常结肠组织中的表达和分布情况。结果:HER4在结肠癌组织及良性结肠组织中均有表达,但在良性结肠组织中呈非过度表达,而在结肠癌组织中呈过度表达(P=0.023)。HER4在Dukes分期为A期的结肠癌组织中均呈非过度表达,B期过度表达率为35.71%,C期过度表达率为75.00%,D期过度表达率为80.00%,存在统计学差异(P=0.028)。有淋巴结转移的结肠癌组织中过度表达率为75.00%,而无淋巴结转移的结肠癌组织中过度表达率为35.48%,结果存在统计学差异(P=0.010)。结论:HER4在结肠癌组织中的过度表达明显增强,并且与结肠癌的临床分期密切相关,临床分期较晚的患者HER4过度表达较高。HER4在结肠癌组织中的过度表达预示着肿瘤的恶性程度更高,生物攻击行为更强,发生潜在转移的可能性更大。
目的:研究HER4在結腸癌中的錶達併探討其臨床意義。方法:選擇47例經哈爾濱醫科大學附屬腫瘤醫院病理科確診的結腸癌術後蠟塊標本重新切片,經HE染色併由該院病理科醫生重新閱片確診;另取6例術後經病理檢查證實為非噁性的結腸組織(視為良性結腸組織)作為對照,應用免疫組織化學方法(SP法)檢測HER4在結腸癌各組癌組織及正常結腸組織中的錶達和分佈情況。結果:HER4在結腸癌組織及良性結腸組織中均有錶達,但在良性結腸組織中呈非過度錶達,而在結腸癌組織中呈過度錶達(P=0.023)。HER4在Dukes分期為A期的結腸癌組織中均呈非過度錶達,B期過度錶達率為35.71%,C期過度錶達率為75.00%,D期過度錶達率為80.00%,存在統計學差異(P=0.028)。有淋巴結轉移的結腸癌組織中過度錶達率為75.00%,而無淋巴結轉移的結腸癌組織中過度錶達率為35.48%,結果存在統計學差異(P=0.010)。結論:HER4在結腸癌組織中的過度錶達明顯增彊,併且與結腸癌的臨床分期密切相關,臨床分期較晚的患者HER4過度錶達較高。HER4在結腸癌組織中的過度錶達預示著腫瘤的噁性程度更高,生物攻擊行為更彊,髮生潛在轉移的可能性更大。
목적:연구HER4재결장암중적표체병탐토기림상의의。방법:선택47례경합이빈의과대학부속종류의원병이과학진적결장암술후사괴표본중신절편,경HE염색병유해원병이과의생중신열편학진;령취6례술후경병리검사증실위비악성적결장조직(시위량성결장조직)작위대조,응용면역조직화학방법(SP법)검측HER4재결장암각조암조직급정상결장조직중적표체화분포정황。결과:HER4재결장암조직급량성결장조직중균유표체,단재량성결장조직중정비과도표체,이재결장암조직중정과도표체(P=0.023)。HER4재Dukes분기위A기적결장암조직중균정비과도표체,B기과도표체솔위35.71%,C기과도표체솔위75.00%,D기과도표체솔위80.00%,존재통계학차이(P=0.028)。유림파결전이적결장암조직중과도표체솔위75.00%,이무림파결전이적결장암조직중과도표체솔위35.48%,결과존재통계학차이(P=0.010)。결론:HER4재결장암조직중적과도표체명현증강,병차여결장암적림상분기밀절상관,림상분기교만적환자HER4과도표체교고。HER4재결장암조직중적과도표체예시착종류적악성정도경고,생물공격행위경강,발생잠재전이적가능성경대。
Objective:To investigate the expressinn of HER4 in colon carcinoma and the possible significance. Methods:The specimens were taken from 47 colon carcinoma tissues and 6 normal colon tissues from the affiliated tumour hospital of Harbin medi-cal university.SP immunohistochemistry was used to evaluate the expression of HER4 in 47 colon carecnoma tissues and 6 normal co-lon tissues. Results:HER4 is expressed both in colon carcinoma tissues and normal colon tissues,but there is no overexpression of HER4 in normal colon tissues,and the overexpression rate of HER4 in colon carcinoma was 48.94%(P=0.023). The overexpression rate of HER4 was seen in 0%(0/2)Dukes stage A cases,35.71%(10/28)stage B cases,75.00%(9/12)stage C cases and 80.00%(4/5) stage D cases(P=0.028).12 of 16(75.00%)cases with metastasis of lymphnode have overexpression expression of HER4,while only 11 of 31(35.48%)cases without metastasis of lymph node(P=0.010). Conclusions:The overexpression of HER4 is elevated in colon carcinoma,and its overexpression is significantly associated with clinical stage. HER-4 overexpression status may prognosticate colon carcinoma with more malignant level,more aggressive biological behavior and more increased metastatic potential.